Welcome to the post-event wrap-up of the largest TIDES Asia event to date. On March 19-21, 2024, more than 300 attendees from across the global oligo, peptide, mRNA, genome editing community gathered in Kyoto, Japan, to discuss the latest cutting-edge strategies to accelerate molecules to market.
The TIDES Asia agenda encompassed over 70 speakers across two tracks. Notable speakers included Shalini Andersson, Ph.D., from AstraZeneca in Sweden, who discussed the development of next-generation oligonucleotide therapeutics. Her talk centered on the latest advancements in oligonucleotide discovery, highlighting innovative techniques and potential therapeutic applications. Kousaku Ohinata, Ph.D., from Kyoto University and Viage Therapeutics, presented on the development of a novel bioactive peptide that targets the gut-brain axis to enhance mood and cognition, showcasing the translation of basic research into clinical applications. Andrew Bellinger, M.D., Ph.D., from Verve Therapeutics, discussed genetic editing strategies aimed at combating atherosclerotic cardiovascular disease. Finally, Andreas Czech, Ph.D., of BioNTech SE in Germany, discussed strategies for mRNA analytics, focusing on the technical challenges and solutions in mRNA-based therapies.
The conference also featured presentations from Jayaprakash Nair, Ph.D., of Alnyla, who spoke about the discovery and delivery of oligonucleotide therapeutics, further enriching the discussion on this pioneering field.
This eBook highlights key moments of the event and looks at the significance of the research and insights shared throughout the three days in Kyoto. Read on to get a sense of what the buzz was like on-site and learn more about the industry-shaping discussions that were shared at TIDES Asia.
We hope to see you next year at TIDES Asia on Feb. 26-28, 2025, in Kyoto.
Click to read eBook: TIDES Asia Post-Event Report
